One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Grifols SA - ADR before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Grifols SA - ADR’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Grifols SA - ADR’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Grifols SA - ADR (GRFS)

Before we jump into Grifols SA - ADR’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

Want to learn more about Grifols SA - ADR’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Grifols SA - ADR. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Grifols SA - ADR’s Stock Price as of Market Close

As of May 31, 2023, 4:00 PM CST, Grifols SA - ADR’s stock price was $8.24.

Grifols SA - ADR is down 4.3% from its previous closing price of $8.61.

During the last market session, Grifols SA - ADR’s stock traded between $8.55 and $8.85. Currently, there are 678.41 million shares of Grifols SA - ADR stock available for purchase.

Grifols SA - ADR’s price-earnings (P/E) ratio is currently at 26.3, which is high compared to the Pharmaceuticals industry median of 18.8. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Grifols SA - ADR Stock Price History

Grifols SA - ADR’s (GRFS) price is currently up 10.46% so far this month.

During the month of May, Grifols SA - ADR’s stock price has reached a high of $9.08 and a low of $7.08.

Over the last year, Grifols SA - ADR has hit prices as high as $13.10 and as low as $5.71. Year to date, Grifols SA - ADR’s stock is down 26.63%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Grifols SA - ADR Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 30, 2023, there were analysts who downgraded Grifols SA - ADR’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Grifols SA - ADR’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Grifols SA - ADR’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Grifols SA - ADR (GRFS) by visiting AAII Stock Evaluator.

Relative Price Strength of Grifols SA - ADR

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of May 30, 2023, Grifols SA - ADR has a weighted four-quarter relative price strength of -8.41%, which translates to a Momentum Score of 41 and is considered to be Average.

Want to learn more about how Grifols SA - ADR is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Grifols SA - ADR Stock Price: Bottom Line

As of May 31, 2023, Grifols SA - ADR’s stock price is $8.24, which is down 4.3% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Grifols SA - ADR’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.